Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp., a leader in microdosing treatments for mental health, has signed a $66.5 million non-binding term sheet with Enveric Biosciences to out-license a novel psilocin prodrug candidate aimed at treating neuropsychiatric conditions without the hallucinogenic side effects. The deal could potentially lead to MindBio receiving an exclusive global license to develop and commercialize the NPP compounds, with a royalty agreement in place upon successful advancement of the drug candidate.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
